<DOC>
	<DOCNO>NCT00034749</DOCNO>
	<brief_summary>A clinical study compare safety effectiveness two different dose range risperidone solution treatment adolescent diagnosis schizophrenia .</brief_summary>
	<brief_title>The Efficacy Safety Risperidone Treatment Adolescents With Schizophrenia</brief_title>
	<detailed_description>This clinical study investigational drug call risperidone treatment schizophrenia adolescent . Initially child ( age 2 12 yr ) schizophreniform subject also allow exclude follow protocol amendment . The study include approximately 260 patient age 13 17 year diagnosis schizophrenia . Subjects randomly assign one two group enrollment give risperidone oral solution day 8 week dose within one two dose different range , accord assign study group . Initially two dose range 0.15-0.4 mg/day 1.5-4mg/day change protocol amendment evaluate maximum tolerate dose minimum 3.5mg/day maximum 6mg/day ( resp . 0.35 0.6mg/day low dose treatment arm ) Risperidone low dose ( 0.35-0.6 mg/day [ subject &gt; =50kg ] 0.007-0.012 mg/kg/day [ subject &lt; 50 kg ] ) 0.1 mg/mL oral solution risperidone high dose ( 3.5-6 mg/day [ subject &gt; =50 kg ] 0.07-0.12 mg/kg/day [ subject &lt; 50 kg ] ) 1 mg/mL oral solution 8 week . Daily dose give 2 administration ( morning evening ) ; dose increase base efficacy tolerability .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Subjects eligible study enrollment : adolescent age 13 17 year confirm diagnosis schizophrenia suffer acute episode provide assent parental inform consent participate otherwise relatively healthy basis medical physical examination able inpatient approximately 2 week . Subjects exclude study : meet criterion psychiatric disorder schizophrenia moderate severe mental retardation fail respond treatment least two typical atypical antipsychotic history substance dependence within 3 month screen consider risk suicidal violent behavior seizure disorder history neuroleptic malignant syndrome , similar encephalopathic syndrome , tardive dyskinesia receive prohibit medication within specified period screening .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>risperidone</keyword>
</DOC>